Aisling Capital’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Aisling Capital’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-50,857	Closed	-$4.95M	–	11
2017 Q4	$4.95M	Hold	50,857	–	–	0.98%	8
2017 Q3	$7.49M	Hold	50,857	–	–	1.23%	10
2017 Q2	$8.18M	Hold	50,857	–	–	1.4%	8
2017 Q1	$8.1M	Hold	50,857	–	–	1.47%	11
2016 Q4	$6.18M	Hold	50,857	–	–	1.44%	13
2016 Q3	$7.05M	Sell	50,857 -40,000	-44%	-$5.08M	1.45%	14
2016 Q2	$16.5M	Buy	+90,857	New	+$16.5M	3.89%	11

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Aisling Capital's SYRS Position: Q1 2018 in Review

Aisling Capital sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2018, closing a stake of 50,857 shares — an estimated $4.95M sold.

Aisling Capital first reported a position in SYRS in Q2 2016 and held it in 7 quarters. The position peaked at $16.5M in Q2 2016. 57 funds tracked by Wall St. Rank hold SYRS as of Q1 2018.

Aisling Capital reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Aisling Capital sold 50,857 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2018, an estimated $4.95M.
Aisling Capital first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2016 and held it in 7 quarters.
Aisling Capital's Syros Pharmaceuticals, Inc. Common Stock position peaked at $16.5M in Q2 2016.
57 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2018.

Based on Aisling Capital's 13F filing for Q1 2018, filed 14 May 2018.